183 related articles for article (PubMed ID: 26713838)
1. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy for advanced renal cell cancer].
Schmidt S; Kunath F; Kroeger N
Urologe A; 2015 May; 54(5):716-20. PubMed ID: 25987336
[No Abstract] [Full Text] [Related]
5. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
6. Chemo-immunotherapy in RCC: the end of a story.
Escudier B
Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
[No Abstract] [Full Text] [Related]
7. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
8. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of extensive metastatic renal cancer following immunotherapy.
Plowman PN; Costello J; O'Donoghue N
Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
[TBL] [Abstract][Full Text] [Related]
10. Present achievements in the medical treatment of metastatic renal cell carcinoma.
Ravaud A; Debled M
Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192
[No Abstract] [Full Text] [Related]
11. In focus: bevacizumab for renal cell carcinoma.
Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
[No Abstract] [Full Text] [Related]
12. New challenges in kidney cancer therapy: bevacizumab.
Ravaud A
Ann Oncol; 2007 Jul; 18 Suppl 9():ix89. PubMed ID: 17631602
[No Abstract] [Full Text] [Related]
13. Removing the primary tumor after the cancer has spread.
Tannock IF
N Engl J Med; 2001 Dec; 345(23):1699-700. PubMed ID: 11759650
[No Abstract] [Full Text] [Related]
14. The role of adoptive immunotherapy in solid cancers.
Kruit WH; Stoter G
Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332
[No Abstract] [Full Text] [Related]
15. Novel investigative approaches for advanced renal cell carcinoma.
Berg WJ; Divgi CR; Nanus DM; Motzer RJ
Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
Linehan WM; Walther MM; Alexander RB; Rosenberg SA
Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
[No Abstract] [Full Text] [Related]
18. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
Taneja SS; Pierce W; Figlin R; Belldegrun A
Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
[No Abstract] [Full Text] [Related]
19. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?
Margulis V; Wood CG
Eur Urol; 2008 Sep; 54(3):489-92. PubMed ID: 18206292
[No Abstract] [Full Text] [Related]
20. Cytoreductive nephrectomy in metastatic renal cancer.
Flanigan RC
Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
